Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …

The aim of the current study is to identify the human cytochrome P450 (P450) isoforms
involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically …

Clopidogrel is a pro‐drug which is converted to an active metabolite that selectively blocks
ADP‐dependent platelet activation and aggregation. The main enzyme responsible for …

A double‐blind crossover study was conducted in four CYP2C19 genotype–defined
metabolizer groups to assess whether increase in clopidogrel dosing can overcome …

Currently, concerns of clopidogrel and proton pump inhibitors (especially omeprazole)
interaction are raised, because they are both metabolized by CYP2C19. What is more …

Abstract Background and Objectives Resistance to the antiplatelet treatment with clopidogrel
has both genetic and non-genetic causes. Polymorphic variants of cytochrome P450 3A4 …

Clopidogrel and aspirin are among the most prescribed dual antiplatelet therapies to treat
the acute coronary syndrome and heart attacks. However, their potential clinical impacts are …

The thienopyridine, clopidogrel bisulfate (clopidogrel), is the most widely prescribed
antiplatelet therapy in the world. Clopidogrel, alone or in conjunction with aspirin as part of a …

Summary Background Cytochrome P450 2C19 (CYP2C19) is the principal enzyme
responsible for converting clopidogrel into its active metabolite, and common genetic …

The objective of this study was to investigate the contribution of genetic polymorphism of
cytochrome P450 2C19 gene (CYP2C19) and non-genetic factors to clopidogrel in Chinese …